ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0633

Value of the Routine Assessment of Patient Index Data 3 (RAPID3) as a Disease Activity Measure in Patients with Psoriatic Arthritis

Johny Fares1, Andrea Healy1 and Martin Bergman2, 1Main Line Health, Wynnewood, PA, 2Martin Jan Bergman, MD, Ridley Park, PA

Meeting: ACR Convergence 2021

Keywords: Disease Activity, functional status, Psoriatic arthritis, quality of life, RAPID 3

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 7, 2021

Title: Measures & Measurement of Healthcare Quality Poster (0623–0659)

Session Type: Poster Session B

Session Time: 8:30AM-10:30AM

Background/Purpose: The RAPID3 is a patient-reported pooled index of three measures: function, pain, and patient global estimate of status, that is used to classify disease severity1. It was developed in rheumatoid arthritis, but multiple studies have shown that it is useful in many rheumatic diseases, including Psoriatic Arthritis (PsA)2,3. We assessed the correlation of RAPID3 with other standard scores used in PsA in a private clinical practice setting.

Methods: Adult patients with a diagnosis of PsA seen between February 2012 and November 2020 were retrospectively identified. We collected data including demographics, clinical measures and 4 disease activity measures: RAPID3,DAPSA, cDAPSA and CDAI from random routine care visits.

Spearman’s correlations were calculated between RAPID3 and the other scores. Cross-test consistency of disease activity (remission, low, moderate, high) between different scores using kappa agreement analysis was calculated. Using ROC, we assessed the values of RAPID3 which best correlated with these levels of consistency. All calculations were performed using Stata Software v14 (Plano TX). IRB approval was obtained.

Results: The study included 100 patients with PsA. Patients’ characteristics and scores are presented in table 1.

Spearman correlation analysis demonstrated a very strong correlation between RAPID3 and both DAPSA and cDAPSA (r=0.86) as well as a strong correlation between RAPID3 and CDAI (r=0.77).

There was strong agreement between RAPID3 remission score and DAPSA and cDAPSA remission scores, Kappa: 0.78 (p < 0.0001) and 0.71 (p < 0.0001) respectively.
The level of agreement dropped when we combined remission and low activity scores together, Kappa 0.56 (p < 0.0001) and 0.55 (p < 0.0001) respectively, although this remained in the moderate range.

Based on the ROC analysis, we redefined the RAPID3 score categories. A score of ≤3 was considered remission. >3 and ≤11 was considered low disease activity. >11 and ≤15 was considered moderate disease activity and >15 was considered high disease activity. Based on these categories, the level of agreement between RAPID3 and DAPSA and cDAPSA, when combining remission and low activity scores, significantly increased, Kappa 0.72 (p< 0.0001) and 0.71 (p < 0.0001) respectively.

Conclusion: This study supports the hypothesis that RAPID3 is as an effective disease activity measure in PsA. Our results show a strong to very strong correlation between RAPID3 and other standard scores such as DAPSA and cDAPSA used as a quantitative assessment of PsA disease activity at baseline and to measure treatment response. The advantage of RAPID3 compared to other disease activity measures is that it is a simple score that can be filled out entirely by the patients with minimal time or effort from the rheumatologist1,2,3.

We suggest that redefining the RAPID3 score categories to a score < 11 for low disease activity and >15 for high disease activity, will categorize disease activity more accurately.

Ref
1- Pincus, T, et al. The Journal of Rheumatology 35.11 (2008): 2136-2147.
2- Pincus, T et al. Bulletin of the NYU. 70 Suppl 1 (2012): 30-6.
3- Coates, LC et al. Arthritis Care & Research. 70,8 (2018): 1198-1205.

Patients’ demographic characteristics and disease activity measures


Disclosures: J. Fares, None; A. Healy, None; M. Bergman, AbbVie, 2, 6, Amgen Inc., 6, Novartis, 2, 6, Pfizer, 2, 6, Sanofi, 2, 6, Bristol Myers Squibb, 2, Celgene, 2, Genentech, 2, Janssen, 2, Merck, 2, Johnson & Johnson, 11, Sandoz, 1, GSK, 6, Scipher, 2.

To cite this abstract in AMA style:

Fares J, Healy A, Bergman M. Value of the Routine Assessment of Patient Index Data 3 (RAPID3) as a Disease Activity Measure in Patients with Psoriatic Arthritis [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/value-of-the-routine-assessment-of-patient-index-data-3-rapid3-as-a-disease-activity-measure-in-patients-with-psoriatic-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/value-of-the-routine-assessment-of-patient-index-data-3-rapid3-as-a-disease-activity-measure-in-patients-with-psoriatic-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology